FDA leaders say one pivotal trial, not two, should be ‘default’ for drug approvals
FDA leaders say one pivotal trial, not two, should be ‘default’ for drug approvals
본문을 이용할 수 없습니다. 원본 출처를 확인하세요.
FDA leaders say one pivotal trial, not two, should be ‘default’ for drug approvals